Apimeds Financial Statements From 2010 to 2025

APUS Stock   1.76  0.03  1.73%   
Apimeds Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Apimeds Pharmaceuticals' valuation are provided below:
Market Capitalization
24.3 M
Earnings Share
(0.13)
There are over eighty-three available fundamental signals for Apimeds Pharmaceuticals US,, which can be analyzed over time and compared to other ratios. All traders should validate Apimeds Pharmaceuticals' prevailing fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Enterprise Value is likely to drop to about 20.6 M in 2025
Check Apimeds Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Apimeds Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 123.6 K, Selling General Administrative of 749.4 K or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Apimeds financial statements analysis is a perfect complement when working with Apimeds Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Apimeds Stock
Check out the analysis of Apimeds Pharmaceuticals Correlation against competitors.

Apimeds Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets12.4 K13.1 K157.5 K
Pretty Stable
Short and Long Term Debt Total529 K596.8 K428.3 K
Slightly volatile
Total Current Liabilities1.1 MM166.9 K
Slightly volatile
Accounts Payable26.1 K42.4 K16.9 K
Slightly volatile
Cash3.3 K3.5 K155 K
Pretty Stable
Long Term Debt282.7 K346.8 K381 K
Slightly volatile
Cash And Short Term Investments3.3 K3.5 K155 K
Pretty Stable
Common Stock Shares Outstanding10.2 M11.4 M12.5 M
Slightly volatile
Liabilities And Stockholders Equity12.4 K13.1 K157.5 K
Pretty Stable
Non Current Liabilities Total282.7 K346.8 K381 K
Slightly volatile
Other Current AssetsK9.6 K3.1 K
Slightly volatile
Other Stockholder Equity2.3 MM1.5 M
Slightly volatile
Total Liabilities795.2 K1.4 M512.8 K
Slightly volatile
Total Current Assets12.4 K13.1 K157.5 K
Pretty Stable
Capital Stock71.6 K71.1 K95.1 K
Slightly volatile
Common Stock133.2 K79 K107.4 K
Slightly volatile
Other Current Liabilities813.1 K774.3 K124.7 K
Slightly volatile
Short and Long Term Debt204 K225 K253.7 K
Slightly volatile
Short Term Debt204 K225 K253.7 K
Slightly volatile

Apimeds Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense123.6 K117.7 K24.3 K
Slightly volatile
Selling General Administrative749.4 K1.3 M581.2 K
Slightly volatile
Other Operating ExpensesM1.3 M994.3 K
Pretty Stable
Total Operating ExpensesM1.3 M994.3 K
Pretty Stable

Apimeds Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow236.5 K410.5 K497.5 K
Slightly volatile
Other Non Cash Items123.6 K117.7 K24.3 K
Slightly volatile
Total Cash From Financing Activities561.4 K326.5 K437.7 K
Slightly volatile
End Period Cash Flow3.3 K3.5 K155 K
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables23.2 K21.2 K23.2 K
Slightly volatile
Cash Per Share3.0E-43.0E-40.0135
Pretty Stable
Income Quality0.770.52770.775
Slightly volatile
Current Ratio0.01210.012712.339
Slightly volatile
Interest Debt Per Share0.03670.0620.038
Slightly volatile
Debt To Assets31.1245.710713.2684
Slightly volatile
Ebt Per Ebit0.841.09011.006
Very volatile
Quick Ratio0.01210.012712.339
Slightly volatile
Cash Ratio0.00320.003412.2805
Slightly volatile
Debt Ratio31.1245.710713.2684
Slightly volatile

Apimeds Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap20.3 M22.8 M24.9 M
Slightly volatile
Enterprise Value20.6 M26 M25.3 M
Slightly volatile

Apimeds Fundamental Market Drivers

About Apimeds Pharmaceuticals Financial Statements

Apimeds Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Apimeds Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Apimeds Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Apimeds Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Apimeds Stock Analysis

When running Apimeds Pharmaceuticals' price analysis, check to measure Apimeds Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apimeds Pharmaceuticals is operating at the current time. Most of Apimeds Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apimeds Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apimeds Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apimeds Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.